Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07739498
Recruiting Not applicable

Posterior Resin Bite Turbos Effect on Maxillary Expansion Using a HYRAX Expander in Early Adolescents

NCT07739498 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mansoura University
Phase
Not applicable
Started
2026-02-15
Last updated
2026-08-17

Condition(s) studied

Maxillary Transverse Deficiency (Posterior Crossbite) in Early Adolescent Patients

Investigational drug(s) / intervention(s)

Intervention 1: HYRAX expander with posterior disarticulatory resin bite turbosIntervention 2 (Control): HYRAX expander alone

Intervention 1: HYRAX expander with posterior disarticulatory resin bite turbos: Description: Arm 1: Participants in this group receive a HYRAX rapid maxillary expansion appliance combined with posterior disarticulatory resin bite turbos. The bite turbos are placed on the posterior teeth to disclude the occlusion, aiming to reduce occlusal interference and potentially enhance skeletal response during maxillary expansion. The HYRAX appliance is activated according to a standardized expansion protocol.

Intervention 2 (Control): HYRAX expander alone: Participants in this group receive a HYRAX rapid maxillary expansion appliance alone without the use of posterior bite turbos. The appliance is activated following the same standardized expansion protocol as the intervention group.

Study summary

This randomized controlled clinical trial aims to evaluate the effect of posterior disarticulatory resin bite turbos on the rate of maxillary expansion using a HYRAX expander in early adolescent patients. Participants will be randomly assigned to receive either maxillary expansion with posterior resin bite turbos or conventional expansion without bite turbos. The study will assess and compare the rate and effectiveness of maxillary expansion between the two groups during the treatment period. Clinical measurements will be recorded to evaluate skeletal and dental changes associated with the intervention.

Eligibility

Sex
ALL
Min age
10 Years
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 10-14 years. 2. Bilateral posterior cross bite. 3. Functional lateral cross bite. 4. Good general and oral health. 5. Normal to decreased vertical height )average FMA 29.7 °± 4.2 °).23 Exclusion Criteria: 1. Patients with cleft lip and palate. 2. Severe facial asymmetry. 3. Anterior open bite. 4. Systemic conditions affecting tooth movement (e.g., diabetes, bone disorders). 5. Previous orthodontic treatment.

Primary outcome measure(s)

  • The effect of occlusal disarticulation on the rate of maxillary expansion by linear measurements made on digital models — Baseline and weekly during the active phase of expansion and after 3 months of retention
    Dental landmarks and measurements on models : d3 :Canine tip. d4: Central fissure of first premolar. d6 :Central fissure of first permanent molar. d\_3( inter canine width): Distance between left and right d3. d\_4 (inter first premolar width) : Distance between left and right d4. d\_6(inter first molar width): Distance between left and right d6.

Trial sites (1)

FacilityCityRegionStatus
Orthodontic Department - Faculty of Dentistry Mansoura University Al Mansurah Egypt Recruiting

More Mansoura University trials in Egypt

Effectiveness of Xenogenic Collagen Matrix in Modification of Mucosal Phenotype Around Dental Implants Active, not recruiting
Rectocele Repair with or Without Internal Sphincter Botulinum Toxin Injection: a Prospective Randomized Trial Active, not recruiting
Stellate Ganglion Block for Prevention of Post Mastectomy Depression Recruiting
Passive Fit of Implant-Supported Frameworks: Digital vs Conventional Impressions Recruiting
Titanium Versus Nano-Carbon CAD/CAM Frameworks for All-on-4 Implant Supported Hybrid Prosthesis. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07739498 on ClinicalTrials.gov ↗ ← All trials in Egypt